



# Glaukos to Present Multiple Scientific Abstracts at the 2026 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting

2026-04-06

ALISO VIEJO, Calif.--(BUSINESS WIRE)-- Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, announced today that its technologies will be featured in various scientific programming at the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting, being held April 10-13, 2026 in Washington, D.C. Glaukos will be exhibiting onsite at booth #407.

In addition, Glaukos is sponsoring an educational symposium in conjunction with ASCRS and EyeWorld entitled "Introducing Epioxa™, the first and only FDA-approved, epithelium-on, oxygen-enriched corneal cross-linking treatment," on Friday, April 10, 2026, from 12:00-1:00 p.m. ET in Room 102 AB at the Walter E. Washington Convention Center. The faculty includes Brandon D. Ayres, MD (moderator); Kenneth A. Beckman, MD; Maanasa Indaram, MD; and Matt Jensen, MBA. Go [here](#) for more information and to register.

## **Key Glaucoma and Corneal Health Presentations (in ET):**

### ***Saturday, April 11, 2026***

- **1:40-1:45 p.m., Arkadiy Yadgarov, MD**  
12-Month Outcomes of Standalone Third-Generation Trabecular Micro-Bypass Stents in Eyes with Open-Angle Glaucoma
- **2:01-2:06 p.m., Michael B. Raizman, MD**  
Design Review and Clinical Plan for Novel Keratoconus Screening Device

### ***Sunday, April 12, 2026***

- **1:40-1:45 p.m., Jasmin Kaur / Savak Teymoorian, MD**  
12-Month Single-Center Outcomes of Travoprost Intracameral Implant in Eyes with Open-Angle Glaucoma or Ocular Hypertension
- **3:35-3:40 p.m., Lisa K. Feulner, MD**  
Real-World Outcomes of Combining Trabecular Micro-Bypass Stents with Intracameral Travoprost Implant or Cataract Surgery

## **On-Demand Posters:**

- **Kenneth A. Beckman, MD**  
Persistence of Epithelium-On Corneal Collagen Cross-Linking Treatment Effect in Patients with Keratoconus
- **John P. Berdahl, MD**  
Safety and Efficacy of the Travoprost Intracameral Implant 75 mcg in Combination with the Trabecular Micro-Bypass System: 3-Month Outcomes
- **Christine N. Funke, MD**  
1-Month Outcomes of Third-Generation Trabecular Micro-Bypass Stents Plus a Travoprost Intracameral Implant with or without Cataract Surgery
- **Steven R. Sarkisian Jr., MD**  
Safety and Efficacy of the Second-Generation Travoprost Intracameral Implant: 3-Month Outcomes of the Initial Open-Label Cohort
- **Zachary D. Vest, MD**  
2-Year Outcomes after Third-Generation Trabecular Micro-Bypass Performed with Phacoemulsification in Patients with Open-Angle Glaucoma

Abstract information can be found at <https://annualmeeting.ascrs.org>.

The ASCRS Annual Meeting is among the largest gatherings of anterior segment physicians, medical personnel and industry executives in the ophthalmic industry. All educational content of the ASCRS Annual Meeting is planned by its program committee, and ASCRS does not endorse, promote, approve or recommend the use of any products, devices, or services.

## **About Glaukos**

Glaukos ([www.glaukos.com](http://www.glaukos.com)) is an ophthalmic pharmaceutical and medical technology company focused on developing and commercializing novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. Glaukos first developed Micro-Invasive Glaucoma Surgery (MIGS) as an alternative to the traditional glaucoma treatment paradigm, launching its first MIGS device commercially in 2012. In 2024, Glaukos commenced commercial launch activities for *iDose*<sup>®</sup> TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical designed to deliver 24/7 glaucoma drug therapy inside the eye for extended periods of time. Glaukos also markets the only FDA-approved corneal cross-linking therapy utilizing a proprietary bio-activated pharmaceutical for the treatment of keratoconus, a rare corneal disorder. Glaukos continues to successfully develop and advance a robust pipeline of novel, dropless platform technologies designed to meaningfully advance the standard of care and improve outcomes for patients suffering from chronic eye diseases.

## **About Epioxa HD / Epioxa**

Indication: EPIOXA™ HD (riboflavin 5'-phosphate ophthalmic solution) 0.239% and EPIOXA™ (riboflavin 5'-phosphate ophthalmic solution) 0.177% are photoenhancers indicated for use in epithelium-on corneal collagen cross-linking for the treatment of keratoconus in adults and pediatric patients aged 13 years and older, in conjunction with the O2n™ System and the Boost Goggles<sup>®</sup>.

Dosage and Administration: EPIOXA HD and EPIOXA are for topical ophthalmic use. NOT for injection or intraocular use. EPIOXA HD and EPIOXA are supplied in single-dose syringes. Discard opened syringes

after use. EPIOXA HD and EPIOXA are for use with the O<sub>2</sub>n System and Boost Goggles only. Refer to the O<sub>2</sub>n System Operator's Manual and Boost Goggles User Guide for device instructions.

**Contraindications:** EPIOXA HD and EPIOXA are contraindicated in patients with known hypersensitivity to benzalkonium chloride or any ingredients in EPIOXA HD and EPIOXA. Epithelium-on corneal collagen cross-linking is contraindicated in aphakic and pseudophakic patients without a UV-blocking intraocular lens.

**Warnings and Precautions:** Corneal collagen cross-linking should be used with caution in patients with a history of herpetic keratitis due to the potential for reactivation of herpes keratitis.

**Adverse Reactions:** The most common adverse reaction was conjunctival hyperaemia (31%). Other adverse reactions, occurring in 5% to 25% of eyes included: corneal opacity (haze), photophobia, punctate keratitis, eye pain, eye irritation, increased lacrimation, corneal epithelium defect, eyelid oedema, corneal striae, visual acuity reduced, dry eye, and anterior chamber flare.

### **About *iDose*<sup>®</sup> TR (U.S.)**

iDose TR (travoprost intracameral implant) is a long duration prostaglandin analog indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT). Made from medical-grade titanium, iDose TR is implanted through the trabecular meshwork and back wall of Schlemm's canal, directly into scleral tissue. Once implanted, 75 mcg of a novel, preservative-free, proprietary formulation of travoprost continuously elutes into the anterior chamber via membrane-controlled diffusion, allowing for 24/7 release of medication.

**Indication for Use:** iDose TR (travoprost intracameral implant) is indicated for the reduction of intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension (OHT).

**Dosage and Administration:** For ophthalmic intracameral administration. The intracameral administration should be carried out under standard aseptic conditions.

**Contraindications:** iDose TR is contraindicated in patients with active or suspected ocular or periocular infections, patients with corneal endothelial cell dystrophy (e.g., Fuch's Dystrophy, corneal guttatae), patients with prior corneal transplantation, or endothelial cell transplants (e.g., Descemet's Stripping Automated Endothelial Keratoplasty [DSAEK]), patients with hypersensitivity to travoprost or to any other components of the product.

**Warnings and Precautions:** iDose TR should be used with caution in patients with narrow angles or other angle abnormalities. Monitor patients routinely to confirm the location of the iDose TR at the site of administration. Increased pigmentation of the iris can occur. Iris pigmentation is likely to be permanent.

**Adverse Reactions:** In controlled studies, the most common ocular adverse reactions reported in 2% to 6% of patients were increases in intraocular pressure, iritis, dry eye, visual field defects, eye pain, ocular hyperaemia, and reduced visual acuity.

### **About *iStent infinite*<sup>®</sup> Trabecular Micro-Bypass System (U.S.)**

**Indication for Use:** The iStent infinite Trabecular Micro-Bypass System Model iS3 is an implantable device intended to reduce the intraocular pressure (IOP) of the eye. It is indicated for use in adult

patients with primary open-angle glaucoma in whom previous medical and surgical treatment has failed.

**Contraindications:** The iStent infinite is contraindicated in eyes with angle-closure glaucoma where the angle has not been surgically opened, acute traumatic, malignant, active uveitic, or active neovascular glaucoma, discernible congenital anomalies of the anterior chamber (AC) angle, retrobulbar tumor, thyroid eye disease, or Sturge-Weber Syndrome or any other type of condition that may cause elevated episcleral venous pressure.

**Warnings:** Gonioscopy should be performed prior to surgery to exclude congenital anomalies of the angle, PAS, rubeosis, or conditions that would prohibit adequate visualization that could lead to improper placement of the stent and pose a hazard.

**MRI Information:** The iStent infinite is MR-Conditional, i.e., the device is safe for use in a specified MR environment under specified conditions; please see Directions for Use (DFU) label for details.

**Precautions:** The surgeon should monitor the patient postoperatively for proper maintenance of IOP. Three out of 61 participants (4.9%) in the pivotal clinical trial were phakic. Therefore, there is insufficient evidence to determine whether the clinical performance of the device may be different in those who are phakic versus in those who are pseudophakic.

**Adverse Events:** The most common postoperative adverse events reported in the iStent infinite pivotal trial included IOP increase  $\geq 10$  mmHg vs. baseline IOP (8.2%), loss of BSCVA  $\geq 2$  lines (11.5%), ocular surface disease (11.5%), perioperative inflammation (6.6%) and visual field loss  $\geq 2.5$  dB (6.6%).

**Caution:** Federal law restricts this device to sale by, or on the order of, a physician. Please see DFU for a complete list of contraindications, warnings, precautions, and adverse events.

For more information, visit [www.glaukos.com](http://www.glaukos.com).

### **Forward-Looking Statements**

All statements other than statements of historical facts included in this press release that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements. Although we believe that we have a reasonable basis for forward-looking statements contained herein, we caution you that they are based on current expectations about future events affecting us and are subject to risks, uncertainties and factors relating to our operations and business environment, all of which are difficult to predict and many of which are beyond our control, that may cause our actual results to differ materially from those expressed or implied by forward-looking statements in this press release. These potential risks and uncertainties include, without limitation, the timing and extent to which obtain regulatory approval for investigational products, our ability to successfully commercialize such products, the ability to obtain and maintain adequate financial coverage and reimbursement for our products, and the continued efficacy and safety profile of our products as might be suggested in the presentations at the ASCRS meeting. Historical, current and forward-looking sustainability-related statements may be based on standards for measuring progress that are still developing, internal controls and processes that continue to evolve, and assumptions that are subject to change in the future. The information included in, and any issues identified as material for purposes of this document may not be considered material for Securities and Exchange Commission (SEC) reporting purposes. In the context of this disclosure, the term "material" is distinct from, and should not be confused with, such term as defined for SEC reporting purposes. These and other risks, uncertainties and factors related to Glaukos, and our

business are described in detail under the caption “Risk Factors” and elsewhere in our Annual Report on Form 10-K for the year ended December 31, 2025, which was filed with the SEC on February 23, 2026. Our filings with the SEC are available in the Investor Section of our website at [www.glaukos.com](http://www.glaukos.com) or at [www.sec.gov](http://www.sec.gov). In addition, information about the risks and benefits of our products is available on our website at [www.glaukos.com](http://www.glaukos.com). All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on the forward-looking statements in this press release, which speak only as of the date hereof. We do not undertake any obligation to update, amend or clarify these forward-looking statements whether as a result of new information, future events or otherwise, except as may be required under applicable securities law.

Media Contact – Glaucoma:  
Silvana Guerci-Lena  
(508) 808-8993  
[GlaukosMedia@powers-co.com](mailto:GlaukosMedia@powers-co.com)

Media Contact – Corneal Health:  
Michele Gray  
(917) 449-9250  
[michele@mgraycommunications.com](mailto:michele@mgraycommunications.com)

Investor Contact:  
Chris Lewis  
Vice President, Investor Relations & Corporate Affairs  
[clewis@glaukos.com](mailto:clewis@glaukos.com)

Source: Glaukos Corporation